Main content

    Brain Health Clinical Trials

    Brain Health Center at California Pacific Medical CenterOpens new window

    Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov

    Active Trials

    Title: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
    Description: The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in participants with early AD
    Investigator: Alireza Atri, MD, PhD
    Eligibility: Subjects, 50 to 85 years old, who have a Clinical Dementia Rating (CDR)-Global Score of 0.5, have objective evidence of cognitive impairment at screening, and an MMSE score between 24 and 30 (inclusive)
    Status: Active and open to enrollment
    Contact: Katharine Vieira, RN, GNP-C, 415-600-5570,Email: Vieirak1@sutterhealth.org about Study Biogen 221AD302
    or
    Contact: Erika Glaubitz, 415-600-4796, Email: GlaubiEA@cpmcri.org about Study Biogen 221AD302

    Title: Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia
    Description: The main purpose of this study is to evaluate the safety and the effect on brain tau of the study drug LY3202626 in participants with mild Alzheimer's disease (AD) dementia
    Investigator: Alireza Atri, MD, PhD
    Eligibility: Subjects, 50 to 85 years old, who have mild AD dementia based on the National Institute on Aging (NIA) and the Alzheimer's Association (AA) disease diagnostic criteria as determined by a qualified clinician approved by the Sponsor or designee, and, who have a Mini-Mental State Examination score of 20 to 26 inclusive at screening visit
    Status: Active and open to enrollment
    Contact: Katharine Vieira, RN, GNP-C, 415-600-5570,Email: Vieirak1@sutterhealth.org about Study Lilly LLCF
    or
    Contact: Erika Glaubitz, 415-600-4796, Email: GlaubiEA@cpmcri.org about Study Lilly LLCF

    Title: Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study: A Coverage With Evidence Development Longitudinal Cohort Study
    Description: The IDEAS Study is an observational, open-label, longitudinal cohort study designed to assess the impact of amyloid PET on patient-oriented outcomes in Medicare beneficiaries with mild cognitive impairment (MCI) or dementia of uncertain etiology.
    Investigator: Alireza Atri, MD, PhD
    Eligibility: Subjects, 65 years and older, who are Medicare beneficiaries and with a diagnosis of MCI or dementia, according to DSM-IV and/or National Institutes of Aging-Alzheimer's Association criteria, verified by a dementia specialist within 24 months
    Status: Active and open to enrollment
    Contact: Katharine Vieira, RN, GNP-C, 415-600-5570,Email: Vieirak1@sutterhealth.org about Study IDEAS
    or
    Contact: Erika Glaubitz, 415-600-4796, Email: GlaubiEA@cpmcri.org about Study IDEAS

    Title: A Clinico-Pathological Study of the Correspondence Between 18F-AV-1451 PET Imaging and Post-Mortem Assessment of Tau Pathology
    Description: This study is designed to test the relationship between ante-mortem 18F-AV-1451 Positron Emission Tomography (PET) imaging and tau neurofibrillary pathology associated with Alzheimer's disease (AD), as measured at autopsy
    Investigator: Alireza Atri, MD, PhD
    Eligibility: Subjects, 50 years and older, who have a projected life expectancy of ≤ 6 months and who can tolerate a 20 minute PET scan
    Status: Active and open to enrollment
    Contact: Katharine Vieira, RN, GNP-C, 415-600-5570,Email: Vieirak1@sutterhealth.org about Study Avid 18F-AV-1451-A16
    or
    Contact: Erika Glaubitz, 415-600-4796, Email: GlaubiEA@cpmcri.org about Study Avid 18F-AV-1451-A16

    Title: Randomized, Double-blind, Placebo Controlled, Multi-center Registration Trial to Evaluate the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease Receiving Acetylcholinesterase Inhibitors and/or Memantine
    Description: This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer's disease. Patients will receive either azeliragon or placebo with a patient's participation lasting approximately 18 months.
    Investigator: Alireza Atri, MD, PhD
    Eligibility: Subjects, 50 years and older, with a diagnosis of probable Alzheimer Disease (AD) with documented evidence of progression of disease
    Status: Active and closed to enrollment
    Contact: Katharine Vieira, RN, GNP-C, 415-600-5570,Email: Vieirak1@sutterhealth.org about Study TTP488-301
    or
    Contact: Erika Glaubitz, 415-600-4796, Email: GlaubiEA@cpmcri.org about Study TTP488-301

    • updated October 2017

    Back to top